BIO B.V

enabling drug discovery in the ubiquitin field since 2010

Access to well-defined and advanced ubiquitin research tools and ubiquitin-like research tools is of paramount importance for drug development, fundamental research and structural studies. Since we founded our company in 2010, our ubiquitin and ubiquitin-like) research tools have been well-recognized by both Pharma and Academia. Many leading laboratories in the field worldwide use our innovative and custom reagents. We also collaborate with outstanding scientists on research projects to further our insights in this growing field. We are proud that our joint efforts regularly result in publications in high-ranking journals. You can find examples in the "recent publications" section below this page. For an extensive reference list of our publications since 2010, please visit our download center.

Please explore how our ubiquitin research tools expedite the three stages of early drug discovery, i.e. target - lead - lead on target, by clicking on the buttons below:

Identify and validate your target using UbiQ Probes.

Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

Our reagents enable you in lead on target validation and lead optimization.

Identify and validate your target using UbiQ Probes.

Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

Our reagents enable you in lead on target validation and lead optimization.

In our laboratory at the Amsterdam Science Park, UbiQ develops, manufactures, and commercializes research tools such as ubiquitinated peptides, activity-based probes, and activity assay reagents. In addition to ubiquitin, we also make ubiquitin-like variants (SUMO, ISG15, NEDD8, etc.) of our reagents.

It is important to note that all our research tools are “For laboratory research use only, not for use in animals and humans".

With our UbiQ technologies we can synthesize site-selective ubiquitinated peptides and reagents that are not available through biological approaches. Next to our catalogue reagents, we offer a tailored and chemical approach to producing specific ubiquitinated conjugates. This custom ubiquitin synthesis approach allows researchers to design ubiquitin conjugates that are not readily available through biological methods.

  We congratulate Dr Jason Collins from the National Institute of Dental and Craniofacial Research / NIH, Bethesda, USA with the First Poster Prize award at the EMBO ubiquitin conference in Cavtat.    

  We congratulate the Poster Prize awardees at last week's Deubiquitylases and Ubl-proteases conference of the Biochemical Society in Edinburgh!    

  We are happy and proud to announce that we have moved our office and labs to a brand new building at Science Park 301, just a five minutes walk from our old laboratories in the...

We hereby announce the launch of an activity-based probe that is designed to selectively target USP7: K58K(biotin) cRh110-Cys-Ubv(USP7)-PA (UbiQ-314). UbiQ-314 is based on Ub with the following mutations: T7D, L8Y, I13R, E34L, Q40N, L69A, and L71A....

  We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Oncode Institute) were recently awarded a new public-private partnership grant by Health-Holland, which is part of the Dutch Life Sciences &...

September  17 - 20, 2024 Vienna, Austria International Plant Proteostasis Conference 2024 Contact: Farid El Oualid (CSO) (sponsorship)

September 27 - October 1, 2024 Cavtat, Croatia Ubiquitin and ubiquitin-like proteins in health and disease. Contact: Alfred Nijkerk (CEO)

June  24 - 25, 2024 Bilbao, Spain 2nd Severo Ochoa Conference: Ligating the Ubiquitin Family; Physiology, Disease, and Future Directions June 2024 Contact: Farid El Oualid (CSO) (sponsorship)

UbiQ is proud to have contributed a chapter to the Methods in Molecular Biology book series (MIMB,volume 2591), together with the Department of Biochemistry & Structural Biology, University of Texas Health Science Center at San...

UbiQ is proud to have been part of a major collaborative research project focused on studying the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6 and whose results have been reported recently in Nature Communications. Yuan et al. Crystal...

21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2), Dr...

UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances, describing the activity profiling and crystal structures of inhibitor bound SARS-CoV-2 PLpro: Activity profiling and crystal...

Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites. Leishmaniasis is a neglected tropical disease caused by parasites...

UbiQ remains committed to advancing the ubiquitin research landscape through our state-of-the-art reagents and innovative chemical approaches. Our dedication to collaboration and research excellence ensures we remain at the forefront of this dynamic field. Reach out to us by filling out our contact form.